Biopsy Devices Market Research Report by Product (Localization Wires, Needle-based Biopsy Instruments, and Procedure Trays), by Technique (MRI-guided Biopsy, Stereotactic-guided Biopsy, and Ultrasound-guided Biopsy), by Application, by End-user – Global Forecast to 2025 – Cumulative Impact of COVID-19New York, March 29, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Biopsy Devices Market Research Report by Product, by Technique, by Application, by End-user – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05993441/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies – USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Biopsy Devices Market is expected to grow from USD 2,166.70 Million in 2020 to USD 3,111.69 Million by the end of 2025.2. The Global Biopsy Devices Market is expected to grow from EUR 1,899.80 Million in 2020 to EUR 2,728.38 Million by the end of 2025.3. The Global Biopsy Devices Market is expected to grow from GBP 1,688.93 Million in 2020 to GBP 2,425.54 Million by the end of 2025.4. The Global Biopsy Devices Market is expected to grow from JPY 231,241.95 Million in 2020 to JPY 332,096.17 Million by the end of 2025.5. The Global Biopsy Devices Market is expected to grow from AUD 3,146.33 Million in 2020 to AUD 4,518.58 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Biopsy Devices to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Product, the Biopsy Devices Market studied across Localization Wires, Needle-based Biopsy Instruments, and Procedure Trays. The Needle-based Biopsy Instruments further studied across Core Biopsy Devices and Vacuum-assisted Biopsy Devices. Based on Technique, the Biopsy Devices Market studied across MRI-guided Biopsy, Stereotactic-guided Biopsy, and Ultrasound-guided Biopsy. Based on Application, the Biopsy Devices Market studied across Breast Biopsy, Colorectal Biopsy, Lung Biopsy, and Prostate Biopsy. Based on End-user, the Biopsy Devices Market studied across Academic and Research Institutes, Diagnostic and Imaging Centers, and Hospitals. Based on Geography, the Biopsy Devices Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biopsy Devices Market including Angiotech Pharmaceuticals, Inc., Argon Medical Devices, Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific Corporation, C. R. Bard, Inc., Cardinal Health, Inc., Cook Group Incorporated, Creganna, Devicor Medical Products, Inc., DTR Medical Ltd, Focal Therapeutics, Inc., Fujifilm Holdings Corporation, Gallini S.r.l., Hologic, INC., Inrad, Inc., Integra LifeSciences Corporation, Leica Biosystems, Medtronic PLC, Olympus Corporation, Precision Biopsy, LLC, Scion Medical Technologies, LLC, and TSK Laboratory Europe BV. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biopsy Devices Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Biopsy Devices Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biopsy Devices Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biopsy Devices Market?4. What is the competitive strategic window for opportunities in the Global Biopsy Devices Market?5. What are the technology trends and regulatory frameworks in the Global Biopsy Devices Market?6. What are the modes and strategic moves considered suitable for entering the Global Biopsy Devices Market?Read the full report: https://www.reportlinker.com/p05993441/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.
The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.
“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.
The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.
But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.
Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.
“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.
“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”
Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.
The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.
In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.
Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.
The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.
The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.
Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.
Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.
It will also re-evaluate its design ranks.
Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.
Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.
This report by The Canadian Press was first published Sept. 13, 2024.
VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.
No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.
About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.
Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.
Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.
A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”
This report by The Canadian Press was first published Sept. 12, 2024.
MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.
The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.
The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.
Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.
On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.
Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.
This report by The Canadian Press was first published Sept. 12, 2024.
